News


The US Food and Drug Administration (FDA) has approved tofacitinib (Xeljanz/Xeljanz XR, Pfizer) for treatment of adults with active psoriatic arthritis (PsA) who have failed to respond adequately or are intolerant to methotrexate or other disease-modifying antirheumatic drugs (DMARDs), according to a company news release.

Tofacitinib, a selective oral Janus kinase (JAK) inhibitor, interrupts signaling of several cytokines involved in immune response. It was first approved by the FDA in 2012 for adults with moderately to severely active rheumatoid arthritis (RA) who have not responded adequately to, or are intolerant of, methotrexate ..

http://www.empr.com/…/xeljanz-tofacitinib-p…/article/718858/